SLC2A1 and hepatocellular carcinoma: Treatment with sanguinarine was found to reduce the glycolysis rate in HCC cells; as evidenced by a decrease in extracellular acidification rate (ECAR) and levels of the key glycolysis enzymes GLUT1, LDHA, and PKM2.